Bosutinib

• Background:

  An ATP-competitive dual Src/Abl kinase inhibitor (IC50 = 1 nM) .1 It potently inhibits the apoptosis-linked STE20 kinases but does not inhibit Kit or PDGFR.2 Bosutinib was found to inhibit 16 of 18 imatinib-resistant mutant forms of Bcr-Abl expressed in murine myeloid cell lines, but did not inhibit T315I and V299L mutants.3 Enhances retinoic acid-induced differentiation of HL-60 leukemia cells.4 Suppresses migration and invasion of human breast cancer cells (IC50 = 250 nM which is also the IC50 for inhibition of cellular Src kinase activity in intact tumor cells) .5

• Conjugation:

  Unconjugated

• Buffer:

  Off-white solid

• Storage Conditions:

  -20°C